Table of Contents

• COVID-19 Vaccine and Bladder Cancer: Friend or Foe?

  Kevin Z. Qi, Miriam P. Palomino ... Yujiang Fang

  This is a letter to the editor on the discussion on COVID-19 vaccine and bladder cancer....

  EDITORIAL | Published: 31 Dec 2022

  Annals of Urologic Oncology, Volume 5 (2022), Issue 2

  Pages: 57-58   PDF(228KB)   Views：1201Downloads：3

• Novel Therapeutic Strategies for BCG-unresponsive Non-muscle Invasive Bladder Cancer

  Peng Zhang, Yi Ding

  Development of therapeutic strategies for non-muscle-invasive bladder cancer (NMIBC) that failed intravesical Bacillus Calmette - Guerin (BCG) therapy remains an urgent priority for clinicians. Currently, radical cystectomy is the recommended standard of care treatment options for these patients. Intravesical chemotherapy using gemcitabine and docetaxel are regarded as the most effective treatment...

  REVIEW | Published: 29 Nov 2022

  Annals of Urologic Oncology, Volume 5 (2022), Issue 2

  Pages: 59-67   PDF(1938KB)   Views：1081Downloads：7

• Targeting CTLA-4 in Cancer: Biological Insights with a Focus on Renal Cell Carcinoma

  Juan Wu, Ya-fei Ren ... Dong-sheng Li

  Renal cell carcinoma (RCC) is a complex group of malignant tumors characterized by immunosuppression and high invasiveness. In the majority of patients with advanced renal cell carcinoma, treatment fails to achieve a complete cure post-treatment. Efforts are needed to develop new therapeutics to improve the outcome of renal cell carcinoma. The "immune checkpoint" of T cells has attracted much atte...

  REVIEW | Published: 21 Dec 2022

  Annals of Urologic Oncology, Volume 5 (2022), Issue 2

  Pages: 68-74   PDF(1000KB)   Views：1139Downloads：7

• Research Progress on Ferroptosis as a Therapeutic Strategy in Renal Cell Carcinoma

  Minna Liu, Min Bai ... Peng Zhang

  Renal cell carcinoma (RCC) is a common type of kidney cancer in adults and constitutes approximately 90% of all renal malignancies. Although advancements have been made in the treatment of RCC, the 5 -year survival rate is still low, and new treatment modalities are still required. Ferroptosis is an iron-dependent programmed cell death caused by the accumulation of lipid peroxide products. Recent ...

  REVIEW | Published: 16 Dec 2022

  Annals of Urologic Oncology, Volume 5 (2022), Issue 2

  Pages: 75-80   PDF(886KB)   Views：857Downloads：4

• Recent Advances in Advance Prostate Cancer

  Nishant Lohia

  Prostate cancer being the second most frequent and fifth leading cause of mortality has led to conduct of many new clinical trials and development of newer therapeutic agents. In the last decade with better understanding of biology of disease there is dramatic improvement and sea change in survival outcomes in advanced prostate cancer with advent of chemotherapy, targeted therapy immunotherapy bes...

  REVIEW | Published: 30 Dec 2022

  Annals of Urologic Oncology, Volume 5 (2022), Issue 2

  Pages: 81-88   PDF(525KB)   Views：790Downloads：11

• Long Non-coding RNA INE1 Induced Autophagy Promotes Sensitivity of Prostate Cancer Cells to Cisplatin

  Hezhen Chu, Kongdong Li ... Jun Ma

  Prostate cancer is most prevalent malignancy of males in the world. In recent years, long non-coding RNAs (lncRNAs) were identified, and their functions are associated with prostate cancer initiation and progression. However, their molecular mechanisms still need to be elucidated before the clinical utility. In the present study, we identified the correlation of lncRNA inactivation escape 1 (INE1)...

  RESEARCH | Published: 29 Nov 2022

  Annals of Urologic Oncology, Volume 5 (2022), Issue 2

  Pages: 89-100   PDF(2470KB)   Views：709Downloads：4

• Update on How to Improve the Outcome of Radical Cystectomy: A Systematic Review

  Ahmed M. Moeen, Hassan A Aboul-Ella

  Radical cystectomy (RCX) is the most difficult urologic procedure. It is usually performed in patients with morbidities and associated with a high rate of complications. So, every effort must be done to improve the outcome of this surgery. This systematic review tries to put an up to date analysis of the literature on how to improve the outcome of RCX. Evidence acquisition A systematic literature...

  REVIEW | Published: 19 May 2022

  Annals of Urologic Oncology, Volume 5 (2022), Issue 1

  Pages: 1-7   PDF(1250KB)   Views：1164Downloads：5

• Is Robotic-assisted Partial Nephrectomy an Efficacious and Safe Procedure for Removal of Stage T1 Renal Tumors?

  Deshraj Choudhary, Shams Tabrej Asgarali Ansari ... Saqib Shahab

  Robotic surgery has now evolved as an emerging tool for better and easy operative techniques. The quest for trifecta comprising warm ischemia time less than 25 minutes, negative surgical margins and no perioperative complications seems to be better accomplished by robotic partial nephrectomy, which is likely to become the new standard for minimally invasive partial nephrectomy. It is a prospective...

  RESEARCH | Published: 13 Apr 2022

  Annals of Urologic Oncology, Volume 5 (2022), Issue 1

  Pages: 8-19   PDF(1360KB)   Views：1790Downloads：5

• Study of Immunohistochemical Marker Psma and Ki 67 Expression and Its Relation with Grading in Prostate Carcinoma

  Amit V Varma, Seema Jindal ... Pooja Kesharwani

  Prostate cancer (PCa) is the second most frequent malignancy (after lung cancer) in men worldwide. In prostate cancer, immunohistochemistry (IHC) has an important role in the diagnostic confirmation. Gleason score, tumour volume, surgical margins and Ki-67 index are the most significant prognostic factors. The value of different biomarkers like p53, Ki-67, PSMA, androgen receptor mutations, IGF, E...

  RESEARCH | Published: 30 Aug 2022

  Annals of Urologic Oncology, Volume 5 (2022), Issue 1

  Pages: 20-33   PDF(2310KB)   Views：1156Downloads：7

• Long Term Results of Elective Nodal Salvage Radiotherapy in Oligometastatic Prostate Cancer: A Mono-institutional Series

  Riccardo Vigna-Taglianti, Alberto Boriano ... Elvio Grazioso Russi

  The development of new metabolic diagnostic imaging PET is changing the history of metastatic prostate cancer (pCa), identifying situations of progression with a low disease burden; radiation treatment of metabolically active oligometastatic sites has been shown to be effective to prolong patient survival. In the scenario of oligometastatic disease to pelvic lymph nodes there is no uniform consens...

  RESEARCH | Published: 06 Oct 2022

  Annals of Urologic Oncology, Volume 5 (2022), Issue 1

  Pages: 34-41   PDF(860KB)   Views：957Downloads：4

• Long Non-coding RNA FAM66C Promotes Prostate Cancer Metastasis via JNK-Mediated Proteasome and Lysosomal Pathway

  Zhenqian Qin, Kongdong Li ... Xuefeng Yuan

  A lower expression of lncRNA FAM66C was noted in the most prostate cancer patients. Knockdown of FAM66C in human prostate cancer DU145 and PC-3 cells promoted EMT and cell migration, which was suppressed by proteasomal inhibitor MG132 and lysosomal inhibitor CQ. Knockdown of FAM66C induced JNK signaling, cell migration and invasion, and activation of proteasome and lysosome pathways were suppresse...

  RESEARCH | Published: 29 Nov 2022

  Annals of Urologic Oncology, Volume 5 (2022), Issue 1

  Pages: 42-51   PDF(2010KB)   Views：820Downloads：5

• Pseudoepitheliomatous Hyperplasia: Harbinger of Underlying Squamous Cell Carcinoma - Lessons Learnt

  Sriram Krishnamoorthy, Hariharasudhan Sekar ... J. Sathish Kumar

  Pseudoepitheliomatous hyperplasia (PEH) is a benign condition marked by reactive epithelial proliferation seen in response to various insults like trauma, infection, persistent inflammation and neoplasia. In this report, we discuss a case of a 35-year-old man who presented with a perineal swelling, later turned into a non-healing ulcer, first diagnosed as PEH. Still, after clinical suspicion, a de...

  CASE REPORT | Published: 25 Dec 2022

  Annals of Urologic Oncology, Volume 5 (2022), Issue 1

  Pages: 52-56   PDF(1240KB)   Views：899Downloads：5